Acrux Limited (ASX:ACR)

10.0¢

right-arrow Created with Sketch. 0 (0%)
MCAP $28.36M
Last trade 16.10pm 30/11/2021 20mins delayed

Latest Announcements

29/11/2021ACRAcrux Limited
26/11/2021ACRAcrux Limited
26/11/2021ACRAcrux Limited
26/11/2021ACRAcrux Limited
26/11/2021ACRAcrux Limited
26/11/2021ACRAcrux Limited
23/11/2021ACRAcrux Limited
23/11/2021ACRAcrux Limited

Company Overview

Acrux Limited is an Australia-based pharmaceutical company. The Company is engaged in developing and commercializing a portfolio of generic topical prescription pharmaceutical products which use dermal and transdermal drug delivery technology. The Company's product pipeline includes Evamist, Lenzetto, Jublia, EMLA and Testosterone Topical Solution. The Company's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The products offered by the Company are the testosterone topical solution to treat adult males who have low or no testosterone and Estradiol MDTS to treat moderate to severe hot flushes commonly associated with menopause. It is also developing a range of topical and dermatological generic products for the United States market. The Company operates in the United States, Europe and other markets.

ACR in the news

Acrux (ACR) is launching its topical testosterone treatment, Axiron, in the USACR’s…
Acrux (ACR) gains FDA approval to market its generic version of the…
Acrux (ACR) has wrapped up a share purchase plan that was more…
Acrux (ACR) was up as much as 54 per cent today after…

Search Previous Announcements